Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108


Rapid countermeasure discovery against Francisella tularensis based on a metabolic network reconstruction.

Chaudhury S, Abdulhameed MD, Singh N, Tawa GJ, D'haeseleer PM, Zemla AT, Navid A, Zhou CE, Franklin MC, Cheung J, Rudolph MJ, Love J, Graf JF, Rozak DA, Dankmeyer JL, Amemiya K, Daefler S, Wallqvist A.

PLoS One. 2013 May 21;8(5):e63369. doi: 10.1371/journal.pone.0063369. Print 2013.


Bis-indolic compounds as potential new therapeutic alternatives for tularaemia.

Caspar Y, Sutera V, Boisset S, Denis JN, Maurin M.

Front Cell Infect Microbiol. 2014 Feb 27;4:24. doi: 10.3389/fcimb.2014.00024. eCollection 2014 Feb 27.


In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis.

Johansson A, Urich SK, Chu MC, Sjöstedt A, Tärnvik A.

Scand J Infect Dis. 2002;34(5):327-30.


Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).

Mehboob S, Song J, Hevener KE, Su PC, Boci T, Brubaker L, Truong L, Mistry T, Deng J, Cook JL, Santarsiero BD, Ghosh AK, Johnson ME.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1292-6. doi: 10.1016/j.bmcl.2015.01.048. Epub 2015 Jan 29.


Identification of Francisella tularensis genes encoding exported membrane-associated proteins using TnphoA mutagenesis of a genomic library.

Gilmore RD Jr, Bacon RM, Sviat SL, Petersen JM, Bearden SW.

Microb Pathog. 2004 Oct;37(4):205-13.


The use of resazurin as a novel antimicrobial agent against Francisella tularensis.

Schmitt DM, O'Dee DM, Cowan BN, Birch JW, Mazzella LK, Nau GJ, Horzempa J.

Front Cell Infect Microbiol. 2013 Dec 6;3:93. doi: 10.3389/fcimb.2013.00093. eCollection 2013 Dec 6.


Azithromycin effectiveness against intracellular infections of Francisella.

Ahmad S, Hunter L, Qin A, Mann BJ, van Hoek ML.

BMC Microbiol. 2010 Apr 23;10:123. doi: 10.1186/1471-2180-10-123.


Iron content differs between Francisella tularensis subspecies tularensis and subspecies holarctica strains and correlates to their susceptibility to H(2)O(2)-induced killing.

Lindgren H, Honn M, Salomonsson E, Kuoppa K, Forsberg Å, Sjöstedt A.

Infect Immun. 2011 Mar;79(3):1218-24. doi: 10.1128/IAI.01116-10. Epub 2010 Dec 28.


Comparative proteome analysis of fractions enriched for membrane-associated proteins from Francisella tularensis subsp. tularensis and F. tularensis subsp. holarctica strains.

Pavkova I, Reichelova M, Larsson P, Hubalek M, Vackova J, Forsberg A, Stulik J.

J Proteome Res. 2006 Nov;5(11):3125-34.


Mechanisms of heme utilization by Francisella tularensis.

Lindgren H, Lindgren L, Golovliov I, Sjöstedt A.

PLoS One. 2015 Mar 10;10(3):e0119143. doi: 10.1371/journal.pone.0119143. eCollection 2015 Mar 10.


Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching.

Hevener KE, Mehboob S, Su PC, Truong K, Boci T, Deng J, Ghassemi M, Cook JL, Johnson ME.

J Med Chem. 2012 Jan 12;55(1):268-79. doi: 10.1021/jm201168g. Epub 2011 Dec 5.


Animal models of Francisella tularensis infection.

Rick Lyons C, Wu TH.

Ann N Y Acad Sci. 2007 Jun;1105:238-65. Epub 2007 Mar 29. Review.


Identification of genes contributing to the virulence of Francisella tularensis SCHU S4 in a mouse intradermal infection model.

Kadzhaev K, Zingmark C, Golovliov I, Bolanowski M, Shen H, Conlan W, Sjöstedt A.

PLoS One. 2009;4(5):e5463. doi: 10.1371/journal.pone.0005463. Epub 2009 May 8.


Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia.

England K, am Ende C, Lu H, Sullivan TJ, Marlenee NL, Bowen RA, Knudson SE, Knudson DL, Tonge PJ, Slayden RA.

J Antimicrob Chemother. 2009 Nov;64(5):1052-61. doi: 10.1093/jac/dkp307. Epub 2009 Sep 4.


The identification and evaluation of ATP binding cassette systems in the intracellular bacterium Francisella tularensis.

Atkins HS, Dassa E, Walker NJ, Griffin KF, Harland DN, Taylor RR, Duffield ML, Titball RW.

Res Microbiol. 2006 Jul-Aug;157(6):593-604. Epub 2006 Feb 8.


In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.

Urich SK, Petersen JM.

Antimicrob Agents Chemother. 2008 Jun;52(6):2276-8. doi: 10.1128/AAC.01584-07. Epub 2008 Apr 14.


Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis.

Chiu HC, Yang J, Soni S, Kulp SK, Gunn JS, Schlesinger LS, Chen CS.

Antimicrob Agents Chemother. 2009 Jul;53(7):2998-3002. doi: 10.1128/AAC.00048-09. Epub 2009 Apr 27.


Structural enzymology and inhibition of the bi-functional folate pathway enzyme HPPK-DHPS from the biowarfare agent Francisella tularensis.

Shaw GX, Li Y, Shi G, Wu Y, Cherry S, Needle D, Zhang D, Tropea JE, Waugh DS, Yan H, Ji X.

FEBS J. 2014 Sep;281(18):4123-37. doi: 10.1111/febs.12896. Epub 2014 Jul 23.

Supplemental Content

Support Center